Abstract
IntroductionIvacaftor was the first therapy licensed to address the underlying defect in cystic fibrosis (CF). The improvements in lung function, nutritional status and pulmonary exacerbations in patients carrying a Gly551Asp...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have